Isla Campbell

Buru Energy raises A$5.3M via two-tranche placement to fund Rafael gas project; says optimisations lift pre-tax cash flow 20-47% and IRR to 42-80%.

Immuron delivers double-digit Q3 Travelan growth, led by Australia +15% to AUD 0.9m; Canada doubles; global Q3 sales AUD 1.5m +16%.

NZ King Salmon lifts FY26 guidance on strong summer farming; expects NZ$19–27m earnings, pro-forma EBIT NZ$10–18m, harvest up to 6,100t.

Eden Innovations launches EdenShield, defence-focused CNT concrete additives; $4.05m placement funds rapid expansion and dual-fuel backup power push.

West Coast Silver discovers drill-ready DHEM conductor at Elizabeth Hill, aligning with historic high-grade silver; immediate drill test underway.

Lightning Minerals pivots to gold with Mt Turner as flagship; 20.4m @ 2.4 g/t Au incl 1.9m @ 10.5 g/t Au; May 2026 drilling; divests lithium to unlock value.

BlinkLab raises oversubscribed A$17.5m to push FDA autism Dx1 clearance and start ADHD Dx2 trials; Morocco rollout underpins real-world data.

DGL Group H1: revenue down 5.8% to $225.2m; NPAT loss, yet advancing NSW waste plant, Unanderra recycling and ERP as ASX trading resumes.

Taiton Resources begins Yogi IOCG drilling as it raises $1.25m to fund Highway Project exploration; assay results expected in June.

Bass Oil mobilises rig for Bunian 6 in Indonesia, targeting 750 bopd total; Bass share ~410 bopd as May–June 2026 production starts.

Hiremii lands its first two paying SaaS customers for AI talent platform, validating market readiness as funding fuels growth.

GSS signs 10-year Danish deal with Hvidovre Hospital for EasyScreen Pan-Enteric; boosts recurring revenue, EMEA growth; first-year 28k samples from Sept 2026.

OD6 Metals hits ultra-high-grade fluorspar at Horseshoe (Quinn NV): 12m @ 68.9% CaF2 (peak 79.7%), open-ended; expands DSO/MetSpar case, Fast 41 potential.

Orthocell wins access to 221 US DoD/VA centres for Remplir, a major US market expansion as HY26 revenue hits A$6.2m and cash sits at A$49.4m.

Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down.

Ovanti secures $5.27m via placement at $0.0101, a 40.4% discount to the last traded price, to fund AI-powered Super App expansion and global BNPL push.

AVITA Medical reports Cohealyx-I interim: mean grafting 13.6 days vs 33.2 benchmark; early grafting, strong clinician adoption signals.

Sprintex secures exclusive Bangladesh distribution for G-Series Jet Blowers, with AU$71k initial PO and multi-year minimums up to AU$2.4m, signaling expansion.

Critica has significantly boosted its Jupiter pilot plant's rare earth recovery rates, achieving 81% MagREO recovery, which de-risks its Scoping Study progress and supports expanded metallurgical

Pointerra wins a three-year Western Power digital twin deal for 50 WA substations, scalable to 155, go-live within 2 weeks; min A$413k.